Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
June 16 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today
announced it successfully completed the rat cohort of a
chronic toxicology study of its lead therapeutic compound ANVS401,
reporting no negative side effects.
The six-month rat study was part of a series of animal
toxicology studies, funded by a $1.7 million grant from the
National Institutes of Health, that began in the fourth quarter of
2019. The safety seen in the rats corroborates the positive results
from the Company’s prior one-month safety studies in mice, rats,
dogs, and humans. A nine-month dog safety study remains ongoing
under the NIH funded program, with results expected in the third
quarter of 2020.
Maria Maccecchini, Ph.D., CEO, commented, “The successful
termination of our chronic rat tox study is another important
milestone for Annovis. Our chronic toxicology studies, which enable
us to conduct long-term human studies, provide a solid foundation
for ANVS401 as we continue to focus on our current ongoing Phase 2a
study in AD and planned two-armed Phase 2a study in PD and AD,
ultimately positioning us to move into pivotal Phase 2/3
studies.”
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc.
(Annovis) is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe
that we are the only company developing a drug for AD, PD and AD-DS
that inhibits more than one neurotoxic protein and, thereby,
improves the information highway of the nerve cell, known as axonal
transport. When this information flow is impaired, the nerve cell
gets sick and dies. We expect our treatment to improve memory loss
and dementia associated with AD and AD-DS, as well as body and
brain function in PD. We have an ongoing Phase 2a study in AD
patients and plan to commence a second Phase 2a study in PD and AD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness and anticipated results of ANVS401 clinical trials
and the approval of any allowances or additional patents.
Forward-looking statements are based on Annovis Bio, Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024